Advancing immunotherapies targeting “dark genome” antigens, specifically HERV-K. Aberrant activation and expression of HERV-K in chronic inflammation, metabolic stress, cancer, and aging — drive immune evasion, senescence, and metabolic dysfunction and disease. By breaking immune tolerance to HERV-K, HERVolution is developing differentiated, off-the-shelf therapies that sit at the intersection of inflammation, type-2 diabetes disease, oncology, and longevity.
| Website | https://hervolutiontx.com/ |
| Employees | 33 (15 on RocketReach) |
| Phone | +45 70 25 25 50 |
| Industry | Biotechnology Research |
| Keywords | Aging Therapeutics, Cancer Treatment, Diabetes Research, Neurodegenerative Diseases, Therapeutic Platform, Immunology Research, Drug Development, Biotechnology, Pharmaceutical Research, Clinical Trials, Health Technology, Life Sciences, Molecular Biology, Disease Treatment, Medical Research, Precision Medicine, Regenerative Medicine |
| Competitors | CARMAhealth, Celyad Oncology, Kite Pharma, Novartis, Gilead Sciences, bluebird bio, Adaptimmune, Fortress Biotech, OncoOne, Amgen +51 more (view full list) |
Looking for a particular Hervolution Therapeutics employee's phone or email?
Hervolution Therapeutics Questions
J. Coleman is the Chairman and CEO of Hervolution Therapeutics.
15 people are employed at Hervolution Therapeutics.
Top Hervolution Therapeutics Employees
-
J. Coleman
Chairman and CEO at Hervolution Therapeutics
New York, NY, US35+ -
Anne-Marie Andersson
CTO at Hervolution Therapeutics
Copenhagen, DK11 -
35+
-
Emeline Ragonnaud
Head of Pre-clinical R and D at Hervolution Therapeutics
Capital Region of Denmark, Denmark3 -
María Penco
Senior Scientist at Hervolution Therapeutics
Copenhagen, DK2 -
Nanna Skeltved
Senior Scientist at Hervolution Therapeutics
Copenhagen, DK1 -
2
G2Crowd Trusted
300K+
Plugin Users
